Avalo Therapeutics, Inc. 8-K

What Happened

• On May 5, 2026, Avalo Therapeutics, Inc. announced positive topline results from its Phase 2 LOTUS trial evaluating the efficacy, safety and tolerability of abdakibart in patients with moderate to severe hidradenitis suppurativa. The company issued a press release and posted a presentation on its website describing the results; both documents were filed as exhibits to the Form 8-K.

Key Details

• Date of filing and disclosures: May 5, 2026 (Form 8-K Items 8.01 and 9.01).
• Trial & drug: Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa.
• Documents filed: Press release (Exhibit 99.1) and presentation (Exhibit 99.2) were attached to the 8-K and posted online. The press release is incorporated by reference except for paragraphs two and five.
• Company note: Avalo stated it has no obligation to update, supplement, or amend the attached press release and presentation.

Why It Matters

• Positive topline Phase 2 results are an important clinical milestone for Avalo’s lead program and may reduce development risk for abdakibart, helping to inform next steps (e.g., later‑stage trials or regulatory planning).
• The 8-K does not provide financial results or revenue impact; investors should review the attached press release and presentation for the detailed data and await company communications on next steps and timing before drawing conclusions.